These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36088429)

  • 1. UBE2T regulates epithelial-mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer.
    Cui P; Li H; Wang C; Liu Y; Zhang M; Yin Y; Sun Z; Wang Y; Chen X
    J Ovarian Res; 2022 Sep; 15(1):103. PubMed ID: 36088429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
    Hao P; Kang B; Li Y; Hao W; Ma F
    Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer.
    Huang W; Huang H; Xiao Y; Wang L; Zhang T; Fang X; Xia X
    Cell Cycle; 2022 Apr; 21(8):780-791. PubMed ID: 35130130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regualting the PI3K/AKT signaling pathway.
    Qiao L; Dong C; Ma B
    J Recept Signal Transduct Res; 2022 Apr; 42(2):151-159. PubMed ID: 33435787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway.
    Wang Y; Leng H; Chen H; Wang L; Jiang N; Huo X; Yu B
    Oncol Res; 2016; 24(5):361-369. PubMed ID: 27712593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT.
    Huang P; Guo Y; Zhao Z; Ning W; Wang H; Gu C; Zhang M; Qu Y; Zhang H; Song Y
    Aging (Albany NY); 2020 Jun; 12(11):10275-10289. PubMed ID: 32491994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UBE2T promotes β-catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK-dependent activation.
    Lioulia E; Mokos P; Panteris E; Dafou D
    Mol Oncol; 2022 Apr; 16(8):1694-1713. PubMed ID: 34614271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irisin/FNDC5 inhibits the epithelial-mesenchymal transition of epithelial ovarian cancer cells via the PI3K/Akt pathway.
    Zhu T; Zhang W; Zhang Y; Lu E; Liu H; Liu X; Yin S; Zhang P
    Arch Gynecol Obstet; 2022 Sep; 306(3):841-850. PubMed ID: 35156135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin-Conjugating Enzyme E2T is an Independent Prognostic Factor and Promotes Gastric Cancer Progression.
    Yu H; Xiang P; Pan Q; Huang Y; Xie N; Zhu W
    Tumour Biol; 2016 Sep; 37(9):11723-11732. PubMed ID: 27020591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway.
    Hu W; Xiao L; Cao C; Hua S; Wu D
    Oncotarget; 2016 Mar; 7(12):15161-72. PubMed ID: 26943030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway.
    Song SZ; Lin S; Liu JN; Zhang MB; Du YT; Zhang DD; Xu WH; Wang HB
    J Cell Physiol; 2019 Aug; 234(10):18587-18601. PubMed ID: 30953349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UBE2T knockdown inhibits gastric cancer progression.
    Luo C; Yao Y; Yu Z; Zhou H; Guo L; Zhang J; Cao H; Zhang G; Li Y; Jiao Z
    Oncotarget; 2017 May; 8(20):32639-32654. PubMed ID: 28427240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-conjugating enzyme E2T regulates cell proliferation and migration in cholangiocarcinoma.
    Liu F; Zhu C; Gao P; Zheng S; Li C
    Anticancer Drugs; 2020 Sep; 31(8):836-846. PubMed ID: 32796405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway.
    Jin Y; Feng SJ; Qiu S; Shao N; Zheng JH
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3176-3184. PubMed ID: 28770968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
    Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
    Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Expression of
    Zou R; Xu H; Li F; Wang S; Zhu L
    DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.